Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial

#1929

Introduction: To date no systematic prospective trials have been carried out to evaluate safety and efficacy of unconventional doses of somatostatin analogs (SSAs) in neuroendocrine tumors (NETs). However,dose escalation of SSAs is a common strategy.

Aim(s): High doses(HD) lanreotide(LAN) therapy in PD NETs

Materials and methods: A multicenter, prospective, open label, single arm phase II study with LAN ATG (180 mg/28 days for 12 months) has been completed in 35 patients (pts) with PD NETs in standard SSAs. Primary endpoint was safety, secondary efficacy

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R,

Keywords: SSA high dose,